转移性前列腺癌患者接受雄激素受体通路抑制剂治疗后出现神经内分泌肿瘤:系统综述与Meta分析
该系统综述与Meta分析纳入8项研究共938例转移性去势抵抗性前列腺癌患者,旨在量化雄激素受体通路抑制剂(ARPI)治疗后治疗相关神经内分泌前列腺癌(t-NEPC)的转变比例,合并分析显示ARPI治疗后NEPC总体频率为16%(95%CI 9-24%),作者认为t-NEPC是mCRPC常被漏诊的晚期并发症,鉴于缺乏诊断生物标志物,应考虑在mCRPC阶段常规重复活检以诊断t-NEPC转变。
要点
- 8项研究共938例mCRPC患者中,171例确诊t-NEPC,主要经病理学确认。
- Meta分析显示ARPI治疗后NEPC总体频率为16%(95%CI 9-24%)。
- 作者认为t-NEPC是mCRPC常被漏诊的晚期并发症。
核心结论
- ARPI相关NEPC是mCRPC中一种常被漏诊的晚期并发症。
研究设计与样本
- 系统综述与Meta分析,检索MEDLINE和Scopus数据库,纳入8项报告既往接受ARPI治疗的mCRPC患者NEPC结局数据的研究,共938例患者。
主要发现
- 8项研究共938例患者中,171例确诊t-NEPC,主要经病理学确认。
- 大多数病例在基线时进行了活检验证以确保无NEPC。
- Meta分析显示ARPI治疗后NEPC总体频率为16%(95%CI 9-24%)。
关键数值与推荐
- 5项研究采用基于组织病理学的形态学定义,3项研究采用循环肿瘤细胞NEPC生物标志物检测。
- 各研究间t-NEPC定义存在差异。
临床怎么用
- 作者认为,鉴于缺乏诊断生物标志物,应考虑在mCRPC阶段常规重复活检以诊断t-NEPC转变。
局限性
- 各研究间t-NEPC定义存在差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: It has been shown that androgen receptor pathway inhibitor (ARPIs) treatment for metastatic castration-resistant prostate cancer (mCRPC) improves overall survival rates, but ARPIs appear to be associated with a higher frequency of treatment-related neuroendocrine prostate cancer (t-NEPC). Our aim was to quantify the proportion of prostate adenocarcinoma cases that transition to t-NEPC following ARPI therapy. METHODS: We conducted a comprehensive search of the literature on t-NEPC using databases including MEDLINE and Scopus. Eligible studies reported outcome data for NEPC in patients with prior mCRPC treated with an ARPI. To determine the pooled frequency of neuroendocrine transformation, the Freeman-Tukey variance-stabilizing arcsine transformation was applied to individual frequencies. KEY FINDINGS AND LIMITATIONS: Among the 938 patients in eight eligible studies, t-NEPC diagnosis was confirmed in 171 patients, predominantly via pathology. Baseline biopsy verification to ensure the absence of NEPC was performed in most cases. The definition of t-NEPC varied among the studies. Five studies used a morphological definition based on histopathology, and three studies used NEPC biomarker detection on circulating tumor cells. A meta-analysis of aggregate data revealed an overall NEPC frequency following ARPI therapy of 16% (95% confidence interval 9-24%). CONCLUSION AND CLINICAL IMPLICATIONS: ARPI-related NEPC represents a frequently underdiagnosed late complication of mCRPC. Given the absence of biomarkers for diagnosis, routine repeat biopsy at the mCRPC stage should be considered to diagnose t-NEPC transitions.
引用
- Séguier D, Parent P, Duterque-Coquillaud M, et al. Emergence of Neuroendocrine Tumors in Patients Treated with Androgen Receptor Pathway Inhibitors for Metastatic Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol Oncol. 2025. PMID: 39824723. doi:10.1016/j.euo.2024.12.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。